BeiGene’s Brukinsa (zanubrutinib) Receives Health Canada’s Approval for Waldenström’s Macroglobulinemia

 BeiGene’s Brukinsa (zanubrutinib) Receives Health Canada’s Approval for Waldenström’s Macroglobulinemia

BeiGene’s Brukinsa (zanubrutinib) Receives Health Canada’s Approval for Waldenström’s Macroglobulinemia

Shots:

  • The approval is based on a P-III APSEN study involve assessing Brukinsa vs ibrutinib in 201 patients with r/r or TN WM who harbor an MYD88 mutation (MYD88MUT). The recommended dose of the therapy is 320mg and is expected to be available in Canada imminently
  • The P-III APSEN study demonstrated clinical benefit with advantages in safety, the combined CR + VGPR rate in the overall ITT population was 28.4% vs 19.2% as assessed by IRC per adaptation of the response criteria updated at the 6th IWWM
  • Brukinsa (BGB-3111) is a BTK inhibitor, currently being evaluated in multiple clinical studies globally as a monothx. or in combination with other therapies targeting B cell malignancies

Click here ­to­ read full press release/ article | Ref: Businesswire  | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post